Neutron Slips to 2027 as Feared; Rocket Lab's Valuation Case Weakens Despite Record Q2

What happened

Rocket Lab has officially pushed Neutron's first launch into 2027, abandoning the previous Q4 2026 target that had already been flagged as narrowing in recent filings. The delay confirms a key risk identified in the company's own 10-K, where management acknowledged the window for an end-of-year 2026 launch was tightening after a January tank qualification failure. While second-quarter revenue surged 62% to a record $234 million, driven by Electron launch cadence and Space Systems growth, the medium-lift Neutron remains central to the company's ability to convert high-value defense contracts like SB-AMTI and SDA programs. The stock has fallen 65% from its May 2026 peak, reflecting the market's prior skepticism, but the formal delay removes a near-term catalyst and pushes the re-rating thesis further out. With Neutron now targeted for 2027, Rocket Lab's valuation must be reassessed against a longer timeline and higher execution risk.

Implication

The delay to 2027 represents a thesis breaker for the medium-lift re-rating story, as it pushes revenue from Neutron-linked defense programs further out and increases uncertainty around contract monetization. Despite record Q2 revenue and strong Electron performance, the core valuation driver has weakened, shifting the probability-weighted value toward the bear case of $52 from the prior base of $72. The next six to nine months now hinge on whether Rocket Lab can disclose specific qualification milestones and a credible first-flight window for 2027, as well as avoid further equity dilution to fund development. Investors should closely monitor cash burn, working capital trends, and any updates on the Iridium acquisition, which adds integration risk and capital demands. A more attractive entry point may emerge if the stock approaches the mid-$50s, but until there is clearer evidence of schedule credibility, a cautious WAIT stance is warranted.

Thesis delta

The investment thesis previously assumed timely Neutron de-risking and a path to first flight by end-2026; the official slip to 2027 invalidates that assumption and weakens confidence in near-term medium-lift revenue conversion. As a result, the probability-weighted fair value shifts from the base case of $72 toward the bear case of $52, and the stock's risk-reward has deteriorated. While the WAIT rating is maintained, conviction decreases, and the attractive entry price may need to be revised below the previous $58 threshold pending evidence of 2027 progress.